Drug Trial Radar · NCT01760005
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
490
Planned (sponsor's estimate)
Start
Dec 2012
Primary completion
Apr 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eli Lilly and Company; Hoffmann-La Roche; Alzheimer's Association; National Institute on Aging (NIA); Avid Radiopharmaceuticals; Accelerating Medicines Partnership (AMP); Eisai Inc.; Janssen, LP
- First posted
- Jan 3, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Conditions
- Alzheimers Disease
- Dementia
- Alzheimers Disease, Familial
Interventions
GantenerumabDrug
Subcutaneously every 4 weeks at escalating doses
SolanezumabDrug
Intravenous infusion every 4 weeks at escalating doses
Matching Placebo (Gantenerumab)Drug
Subcutaneous injection of placebo every 4 weeks
Matching Placebo (Solanezumab)Drug
Intravenous infusion of placebo every 4 weeks
GantenerumabDrug
Open-label administered Subcutaneously every 4 weeks at escalating doses
E2814Drug
Administered intravenously in a blinded fashion
LecanemabDrug
Administered intravenously
Matching Placebo (E2814)Drug
Placebo administered intravenously in a blinded fashion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess cognitive efficacy in individuals with mutations causing dominantly inherited AD as measured by the change from baseline in the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE)Time frame: Baseline and Weeks 52, 104, 156, and 208
Locations
38 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama in Birmingham
Birmingham, Alabama
University of California San Diego Medical Center
La Jolla, California
USC Keck School of Medicine
Los Angeles, California
Yale University School of Medicine
New Haven, Connecticut
Emory University
Atlanta, Georgia
Advocate Lutheran General Hospital
Park Ridge, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
Washington University in St. Louis
St Louis, Missouri
University of Pittsburgh
Pittsburgh, Pennsylvania
Butler Hospital
Providence, Rhode Island
Kerwin Medical Center
Dallas, Texas
University of Washington
Seattle, Washington
Instituto de Investigaciones Neurologicas Raul Carrea, FLENI
Ciudad Autonoma de Buenos Aire, Argentina
Neuroscience Research Australia
Randwick, New South Wales, Australia
Alzheimer's Research Australia
Melbourne, Victoria, Australia
The McCuster Foundation of Alzheimer's Disease Research
Nedlands, Western Australia, Australia
Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, Brazil
CHU de Quebec - Hôpital de l' Enfant Jésus
Québec, Canada
UBC Hospital
Vancouver, British Columbia, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
McGill Center for Studies in Aging
Verdun, Quebec, Canada
Grupo de Neurociencias Sede de la Universidad de Antioquia
Medellín, Colombia
CHU de Toulouse - Hôpital Purpan
Toulouse, Haute Garonne, France
Hopital Roger Salengro - CHU Lille
Lille, Nord, France
Groupe Hospitalier Pitie-Salpetriere
Paris, Paris, France
Hopital Neurologique Pierre Wertheimer
Bron, Rhone, France
CHU de Rouen - Hôpital Charles Nicolle
Rouen, Seine Maritime, France
Universitaetsklinikum Tubingen
Tübingen, Baden-Wurttemberg, Germany
LMU-Campus Grosshadern
Munich, Bavaria, Germany
St Vincent's University Hospital
Dublin, Dublin, Ireland
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Brescia, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
Niigata University Medical & Dental Hospital
Niigata, Niigata, Japan
University of Tokyo Hospital
Bunkyō City, Tokyo-To, Japan
Brain Research Center
Amsterdam, Netherlands
University of Puerto Rico, School of Medicine
San Juan, Puerto Rico, Puerto Rico
Hospital Clínic I Provincial de Barcelona
Barcelona, Barcelona, Spain
The National Hospital for Neurology and Neurosurgery
London, Greater London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.